Press Releases April 13, 2026 08:00 PM

BOSS Zhipin Continues Share Repurchases, with Total Repurchases Amounting to Over RMB835 Million in 2026

KANZHUN LIMITED accelerates share repurchases with over RMB835 million spent in 2026 to enhance shareholder value.

By Jordan Park BZ
BOSS Zhipin Continues Share Repurchases, with Total Repurchases Amounting to Over RMB835 Million in 2026
BZ

KANZHUN LIMITED (BOSS Zhipin) has announced continued share repurchases in 2026, having spent over RMB835 million so far. On April 13, it repurchased 608,328 ordinary shares using RMB27.2 million. This demonstrates the Company's strong commitment to returning value to shareholders through its buyback program.

Key Points

  • KANZHUN LIMITED has repurchased 608,328 shares on April 13, 2026, using RMB27.2 million.
  • Year-to-date 2026 total share repurchases exceed RMB835 million.
  • The buyback program signals a focus on enhancing shareholder returns and confidence in the company's prospects.

BEIJING, April 14, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing over RMB27.2 million to repurchase 608,328 ordinary shares on April 13. Year-to-date in 2026, the Company has deployed over RMB835 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns.


Risks

  • Continued share repurchases might limit liquidity or cash available for other strategic investments, potentially impacting growth opportunities.
  • Market volatility or unexpected economic downturns could affect the company's share price and the effectiveness of the repurchase program.
  • Regulatory changes in the US or Hong Kong markets could impact repurchase activities, given the dual listing status.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026